A recent study examining GIP infusion with semaglutide underscores that short-term physiological experiments do not provide conclusive evidence about tirzepatide’s long-term efficacy, highlighting the importance of understanding drug mechanisms and study limitations.
A recent discussion about tirzepatide has highlighted a basic problem in medical reporting: a negative result about one hormone does not necessarily tell the whole story about a drug that acts on two pathways. In an article on KevinMD, Jeffrey Laman argued that a study published in The Lancet Diabetes & Endocrinology tested the effect of adding natural glucose-dependent insulinotropic polypeptide, or GIP, to semaglutide in adults with type 2 diabetes, not tirzepatide itself. The distinction matters because tirzepatide, the active ingredient in Mounjaro and Zepbound, is a single engineered drug designed to activate both GIP and GLP-1 receptors.
The study was small, short and mechanistically focused. According to the KevinMD summary of the Lancet paper, it enrolled 61 people split across four groups, with 10 participants leaving early. The design included an eight-week semaglutide run-in, followed by six weeks of GIP infusion while semaglutide continued. That makes the work useful for probing short-term physiology, but far less useful for judging the longer-term glucose and weight effects seen in routine treatment with tirzepatide.
The headline finding was that adding GIP to semaglutide did not deliver the large extra drop in glucose that the investigators had expected. But, as Laman noted, the confidence interval was wide enough that the trial could not exclude either a smaller benefit or a smaller harm. The practical takeaway is narrower than some commentary suggested: this dose and duration of natural GIP, given with semaglutide, did not produce the sizeable additional effect the study was powered to detect.
That result sits alongside a broader body of evidence showing tirzepatide remains highly effective in people with diabetes and obesity. A systematic review and meta-analysis indexed on PubMed found that tirzepatide improved glycaemic control and promoted weight loss in type 2 diabetes. The SURPASS-1 phase 3 trial also showed tirzepatide monotherapy significantly improved glucose control versus placebo, while SURPASS-5 found benefit when it was added to basal insulin. Another study in Diabetes reported that tirzepatide improved beta-cell function and insulin sensitivity, strengthening the case that its effects extend beyond simple blood sugar reduction.
Human and clinical data also suggest the GIP component should not be dismissed too quickly. Research on pancreatic islets has shown that blocking the GIP receptor reduces tirzepatide-stimulated insulin secretion, which supports the idea that GIP contributes to the drug’s activity. Large trials have likewise shown that tirzepatide lowers A1C and body weight more than semaglutide in direct comparisons, although those studies do not prove that GIP alone explains the difference. The more cautious reading is that tirzepatide’s benefits may come from the way both receptors work together, or from signalling effects not yet fully understood.
The funding context also deserves notice. The Lancet study was supported by Novo Nordisk, which markets semaglutide, and several investigators disclosed ties to the company and to Antag Therapeutics, which is developing GIP-blocking medicines. That does not invalidate the findings, but it does help explain why readers should focus on trial design, statistics and clinical endpoints rather than headlines alone. Laman also pointed out that the larger tirzepatide studies were funded by Eli Lilly, the company behind the drug. In other words, the evidence base is shaped by commercial research, but it remains the data and the methods that determine how much weight the results should carry.
For patients, the lesson is straightforward. A short experiment with natural GIP plus semaglutide does not overturn the much larger body of evidence showing tirzepatide is one of the most effective options now available for lowering glucose and weight. The more careful conclusion is that the study asked a narrower question than some readers assumed. It tested whether adding infused GIP to semaglutide would produce a large extra metabolic effect over six weeks. It did not test tirzepatide itself. That distinction is not a technicality; it is the difference between a physiology experiment and a verdict on a medicine.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
